Document is current
Any future updates will be listed below
-
Authors
Sahu, Upasana https://orcid.org/0000-0003-2473-9312
Mullarkey, Matthew P.
Murphy, Sara A.
Anderson, Joshua C.
Putluri, Vasanta
Kamal, Abu Hena Mostafa https://orcid.org/0000-0001-6750-0729
Park, Jun Hyoung
Lee, Tae Jin https://orcid.org/0000-0002-5245-1140
Ling, Alexander L.
Kaipparettu, Benny A. https://orcid.org/0000-0003-3444-4307
Sharma, Ashok https://orcid.org/0000-0001-9597-4374
Putluri, Nagireddy https://orcid.org/0000-0003-4488-7400
Wenzel, Pamela L. https://orcid.org/0000-0002-4530-015X
Willey, Christopher D. https://orcid.org/0000-0001-9953-0279
Chiocca, E. Antonio https://orcid.org/0000-0001-5183-1670
Markert, James M. https://orcid.org/0000-0001-7457-7329
Kaur, Balveen https://orcid.org/0000-0001-7738-0804
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA163205, R01CA282282, P30 CA125123)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS127473, R61NS112410)
Georgia Cancer Center Paceline Trainee Research Award
Cancer Prevention and Research Institute of Texas (RP210227)
Dan L. Duncan Cancer Center, Baylor College of Medicine
Cancer Prevention and Research Institute of Texas (CPRIT) Proteomics and Metabolomics Core Facility
- License Information
-
More Information
Article History
Received: 3 July 2024
Accepted: 7 April 2025
First Online: 24 April 2025
Competing interests
: B.K. is an inventor of oHSV-P10 (oP10) which has been licensed to Mesoblast. B.K. does not own any financial shares or interest in Mesoblast. E.A.C. is currently an advisor to Bionaut Labs, Insightec, Inc., Seneca Therapeutics, and Theriva. He has equity options in Bionaut Laboratories, Seneca Therapeutics, and Ternalys Therapeutics. He is a co-founder and on the Board of Directors of Ternalys Therapeutics. He has received research support from NIH, US Department of Defense, American Brain Tumor Association, National Brain Tumor Society, Alliance for Cancer Gene Therapy, Neurosurgical Research Education Foundation, Advantagene, NewLink Genetics, and Amgen. He also is a named inventor on patents related to oncolytic HSV-1 and noncoding RNAs. J.M.M. is a board and equity holding member, in Aettis, Inc., and may receive royalties. The company holds frozen oncolytic viral stocks. Mustang Bio-Tech is licensing the Intellectual Property (IP) of C134, an oncolytic viral Therapy. J.M.M. is blinded to the conditions for the C134 clinical trials. He is a shareholder for a privately held Small Business Innovation Research LLC, Treovir, Inc., concerning G207 oncolytic viral therapy now in clinical trial. Merck, Inc. provides industry grant support by providing Keytruda (pembrolizumab) for a clinical trial of M032 oncolytic virotherapy and financial support for a clinical trial. J.M.M. is a listee on Intellectual Property: 1. related to a cancer immunotherapy system, and 2. to a novel immuno-virotherapeutic strategy targeting the glioma secretome. This IP has been filed by in8Bio (formerly Incysus, Ltd.) and has royalty-earning potential. All other authors declare no competing interests.
